Athira Pharma, Inc. (NASDAQ:ATHA) Sees Significant Decline in Short Interest

Athira Pharma, Inc. (NASDAQ:ATHA) was the target of a large decline in short interest in July. As of July 31st, there was short interest totalling 989,200 shares, a decline of 8.4% from the July 15th total of 1,080,000 shares. Based on an average trading volume of 131,000 shares, the days-to-cover ratio is currently 7.6 days. Currently, 2.8% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, JMP Securities restated a “market outperform” rating and set a $19.00 price objective on shares of Athira Pharma in a research report on Thursday, June 20th.

Insider Transactions at Athira Pharma

In other news, Director Kelly A. Romano purchased 27,400 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were acquired at an average price of $2.42 per share, with a total value of $66,308.00. Following the purchase, the director now directly owns 80,715 shares of the company’s stock, valued at $195,330.30. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Kelly A. Romano acquired 15,000 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The stock was purchased at an average cost of $2.26 per share, for a total transaction of $33,900.00. Following the transaction, the director now directly owns 53,315 shares of the company’s stock, valued at approximately $120,491.90. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Kelly A. Romano acquired 27,400 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The shares were bought at an average price of $2.42 per share, with a total value of $66,308.00. Following the completion of the transaction, the director now directly owns 80,715 shares in the company, valued at $195,330.30. The disclosure for this purchase can be found here. Corporate insiders own 19.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ATHA. Rothschild Investment LLC purchased a new stake in shares of Athira Pharma during the 2nd quarter valued at $34,000. Private Advisor Group LLC purchased a new stake in shares of Athira Pharma during the 4th quarter valued at $32,000. Mirador Capital Partners LP purchased a new stake in shares of Athira Pharma during the 1st quarter valued at $57,000. XTX Topco Ltd purchased a new stake in shares of Athira Pharma during the 2nd quarter valued at $60,000. Finally, Invst LLC purchased a new stake in shares of Athira Pharma during the 2nd quarter valued at $68,000. 57.12% of the stock is currently owned by institutional investors and hedge funds.

Athira Pharma Price Performance

Shares of Athira Pharma stock opened at $2.93 on Monday. Athira Pharma has a 1 year low of $1.33 and a 1 year high of $4.30. The company has a market capitalization of $112.30 million, a P/E ratio of -0.96 and a beta of 2.90. The business has a 50 day moving average price of $2.91 and a 200 day moving average price of $2.80.

Athira Pharma (NASDAQ:ATHA) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.05. As a group, research analysts expect that Athira Pharma will post -2.79 EPS for the current fiscal year.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.